Zymeworks Inc.
NASDAQ:ZYMEBiotechnology
Healthcare
$26.86 -1.64%
-$0.38 today
- Market cap
- $1.87B
- Beta
- 1.14
- P/E (TTM)
- -16.6
- EPS (TTM)
- -$1.37
52W Low $11.51High $29.75
Volume 0.99M
Average 0.71M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$33.01M
FY 2025 · Annual
Investing Cash Flow
$26.66M
FY 2025 · Annual
-31.2% YoYFinancing Cash Flow
-$18.56M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (211.84M) | 124.34M | (118.67M) | (122.7M) | (81.13M) |
| Depreciation & Amortization | 9.58M | 12M | 17.31M | 11.19M | 11.11M |
| Deferred Income Tax | (953K) | 1.94M | (757K) | 691K | 945K |
| Stock-Based Compensation | 10.76M | 4.02M | 8.1M | 17.79M | 28.03M |
| Change in Working Capital | 393K | 4.02M | (25.55M) | (30.95M) | 7.5M |
| Accounts Receivables | (266K) | (17.51M) | 13.92M | (36.36M) | 51.2M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 16.48M | 26.48M | (44.77M) | 14.34M | (23.65M) |
| Other Working Capital | (15.82M) | (4.96M) | 5.3M | (8.93M) | (20.05M) |
| Other Non-Cash Items | (387K) | (2.21M) | 1.27M | 13.93M | 532K |
| Operating Cash Flow | (192.45M) | 144.11M | (118.3M) | (110.04M) | (33.01M) |
| Capital Expenditures | (13.29M) | (13.13M) | (4.08M) | (3.07M) | (1.52M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (35.08M) | (40.72M) | (553.25M) | (283.74M) | (196.06M) |
| Sales of Investments | 192.96M | (40.72M) | 350.07M | 325.57M | 225.08M |
| Other Investing Activities | (881K) | 40.72M | (1.6M) | (1.08M) | 0 |
| Investing Cash Flow | 144.6M | (53.85M) | (207.25M) | 38.76M | 26.66M |
| Debt Repayment | (17K) | (14K) | (21K) | (14K) | 0 |
| Common Stock Issued | 0 | 107.53M | 76.1M | 0 | 23.32M |
| Common Stock Repurchased | 0 | 0 | 0 | (30.05M) | (41.7M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 8.03M | 1.06M | 5.77M | 9.61M | (181K) |
| Financing Cash Flow | 8.01M | 108.58M | 81.85M | (20.45M) | (18.56M) |
| Effect of Forex Changes | (325K) | 203K | 354K | 286K | (45K) |
| Net Change in Cash | (40.17M) | 199.05M | (243.36M) | (91.45M) | (24.95M) |
| Free Cash Flow | (205.74M) | 130.98M | (122.38M) | (113.11M) | (34.53M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$81.1M
+ D&A$11.1M
+ Stock-Based Comp$28.0M
+ Deferred Tax$945.0K
+ Working Capital$7.5M
+ Other Non-Cash$532.0K
= Operating Cash Flow-$33.0M
- Capex-$1.5M
= Free Cash Flow-$34.5M
Analysis
FY2025 free cash flow is -$34.5M. FCF conversion is 42.6% of net income. Operating cash flow was -$33.0M, with capex of -$1.5M. The largest bridge item is Stock-Based Comp at $28.0M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 9, 2026 | |
| 8-K/A | 8-K/A filing | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| ARS | ARS filing | Oct 26, 2026 | |
| DEFA14A | DEFA14A filing | Oct 26, 2026 |
Does ZYME generate free cash flow?
Zymeworks Inc. (ZYME) generated -$34.53M of free cash flow in fiscal 2025.
How much operating cash flow does ZYME produce?
Operating cash flow was -$33.01M, before capital expenditures of $1.52M.
Continue the stock analysis
Jump to another research area for this company.